Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Exclusion Criteria

• •Prior treatment with inclisiran
• •Any other PCSK9 inhibitor (e.g., evolocumab, alirocumab) use within 4 months prior to Screening visit
• •Uncontrolled hypertension at Randomization/Baseline visit
• •Heart failure New York Heart Association (NYHA) class IV at Screening visit or at Randomization/Baseline visit (Day 1)
• •Triglycerides ≥400 mg/dL at Screening visit
• •History of malignancy of any organ system within the past 5 years
• •Myocardial infarction, stroke or other major bleeding, coronary or lower limb re vascularization, major cardiac or non-cardiac surgery between Screening visit and Randomization/Baseline visit (Day 1)
• •Central laboratory reported platelet count \<140,000 per mm3
• •Active liver disease or hepatic dysfunction at Screening visit
• •Significant kidney disease at Screening visit
• •Pregnant or nursing women at Screening visit
• •Any uncontrolled chronic or serious medical condition which may pose an immediate risk to clinical stability of the study participant at Screening visit